Webinar: Quality Delivery of mRNA – LNP with An Unbeatable Timeline

Abstract

Time

Speaker:

• 

  Name: Atsuko Sangria, PhD

  Company: Kudo Biotechnology

  Title: Director, Drug Substance Process Development

  Atsuko Sakurai-Sangria, Ph.D. is the Director of Drug Substance Process Development. Atsuko has 16 years of research experience in molecular biology and vaccine development. Prior to joining Kudo Bio, Atsuko led the mRNA drug substance (DS) process development, scale-up, and technology transfer at RVAC Medicines, a mRNA product company. Previously to RVAC Medicines, Atsuko was an expert scientist at GSK Vaccines, where she played a vital role in mRNA vaccine platform development. She also has preclinical and process development experience in biological products from her past role at VLP Therapeutics and postdoctoral training in the National Institute of Health. Atsuko obtained her Ph.D. in Pharmaceutical Sciences from Kitasato University in Japan.

   

  Read more
• 

  Name: Kelvin Chan, PhD

  Company: Kudo Biotechnology

  Title: Director, Business Development

  Kelvin Chan, PhD, is the Director of Business Development at Kudo Bio. Kelvin is a globally experienced healthcare investor-operator and was formerly Director of Business Development at ABio-X, a CBC Group biotech incubator, as well as Director of Business Development at RVAC Medicines, a mRNA product company. Previously, Kelvin was an operator of several portfolio companies at Tavistock Group. He was formerly a cross-border venture capital investor with EDBI, the strategic investment arm of the Singapore Economic Development Board, investing broadly across healthcare and life sciences. Kelvin holds a PhD in Organic Chemistry from Scripps Research, and conducted his postdoc at the Singapore Bioimaging Consortium. He received his BA (Hons) in Chemistry with First Class Honors at the University of Cambridge, UK. Kelvin is a recipient of the prestigious National Science Scholarship from A*STAR Singapore.

   

  Read more